Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...
Recursion Pharmaceuticals is an AI-enabled drug discovery company, differentiated by its scale and focus on understanding biology. The company has a broad pipeline across various therapeutic areas and ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...
Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback